Phathom Pharmaceuticals, Inc.
PHAT•NASDAQ•Healthcare•Biotechnology

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOSteven Basta
Founded2018
IPO DateOctober 25, 2019
Employees427
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitewww.phathompharma.com
Phone877 742 8466
Address
100 Campus Drive, Suite 102 Florham Park, New Jersey 07932 United States

Corporate Identifiers

CIK0001783183
CUSIP71722W107
ISINUS71722W1071
EIN82-4151574
SIC2834

Leadership Team & Key Executives

Steven L. Basta M.B.A.
Chief Executive Officer, President and Director
David A. Socks
Co-Founder
Dr. Azmi Nabulsi M.D., M.P.H.
Co-Founder
Sanjeev Narula
Chief Financial and Business Officer
Jonathan Bentley
Senior Vice President and Head of Sales, Operations and Training
Robert Breedlove
Vice President of Finance and Principal Accounting Officer
Eric Sciorilli
Director of Business Development and Investor Relations
Bill Aprea J.D.
Senior Vice President, Chief Compliance Officer and Deputy Chief Legal Officer
Anne Marie Cook Esq., J.D.
Chief Legal Officer and Corporate Secretary
Nancy R. Phelan
Senior Vice President of Marketing and Analytics